touchONCOLOGY touchONCOLOGY
Lung Cancer
Read Time: 2 mins

Microwave Ablation of Lung Tumours – Clinical Update

Copy Link
Published Online: May 15th 2012 European Oncology & Haematology, 2012;8(3):192-5 DOI: https://doi.org/10.17925/EOH.2012.08.3.192
Authors: Thomas J Vogl, Nagy Naguib, Tatjana Gruber-Rouh, Nour-Eldin Abdelrehim Nour-Eldin
Quick Links:
Abstract
Article
Article Information
Abstract:
Overview

Thermal ablation offers an intriguing therapeutic option to improve local tumour control and survival in patients with early-stage non-small cell lung cancer or patients with limited metastatic disease from non-lung primaries who are not candidates for surgery, either because of poor cardiopulmonary reserve, anatomic constraints limiting resection, failure of traditional therapies, or refusal of operative approaches. The new field of interventional oncology needs adequate knowledge of the therapeutic tools, advantages and limitations of each method, when and how to apply them, as well as of the new integrative protocols that improve their efficacy. This article provides a clinical review of the role of microwave ablation therapy of primary and metastatic tumours.

Keywords

Microwave, ablation, therapy, lung tumour, metastases

Article:

Lung cancer remains the leading cause of cancer death in the US, accounting for an estimated 29 % of cancer deaths in 2009. Pneumonectomy or lobectomy with hilar and mediastinal lymph node sampling is the gold standard treatment and offers the best option for curing stage 1/2 non-small cell lung cancer (NSCLC),1–5 Unfortunately, only 15 % of patients present with stage 1/2 disease, and many of these do not meet the pulmonary physiologic criteria for lobar resection. In addition to lung cancer, pulmonary metastases are present in 25–30 % of patients dying from all types of cancer. For some patients with oligometastatic pulmonary disease, metastectomy is associated with an improvement in survival. External beam radiation traditionally has been offered as the alternative to surgical resection for NSCLC or pulmonary metastatic disease. Unfortunately, the five-year survival following radiation for stage 1 and 2 NSCLC remains low at 15–20 %, with local recurrence being the most common type of failure.1–5

Thermal ablation offers an intriguing therapeutic option to improve local tumour control and survival in patients with early-stage NSCLC or with limited metastatic disease from non-lung primaries who are not candidates for surgical intervention, either because of poor cardiopulmonary reserve, anatomic constraints limiting resection, failure of traditional therapies or refusal of operative approaches. Thermal ablation has been shown to be effective in treating tumours in bone, kidney and liver. This article offers a clinical update on performing thermal ablation in lung tissue and reviews the current literature regarding microwave (MW) ablation therapy in the lung.

The evolving field of pulmonary interventional oncology can only be considered as a small integrative part in the complex area of oncology. The new field of interventional oncology needs adequate knowledge of the therapeutic tools, advantages and limitations of each method, when and how to apply them, as well as of the new integrative protocols that improve their efficacy. In recent years, several new minimally invasive techniques for the non-surgical treatment of lung malignancies, including percutaneous image-guided ablation therapy, have been developed and refined. Since the first reported use of thermal ablation for lung cancer in 2000, there has been a huge increase in the use of the procedure.6–9

To view the full article in PDF or eBook formats, please click on the icons above.

Article Information:
Disclosure

Thomas J Vogl, Institute for Diagnostic and Interventional Radiology, Johann Wolfgang Goethe University Hospital, Theodor-Stern-Kai 7, 60590 Frankfurt am Main, Germany. E: T.Vogl@em.uni-frankfurt.de

Received

2012-03-02T00:00:00

References

  1. Greene FL, American Joint Committee on Cancer, American Cancer Society, AJCC Cancer Staging Handbook and AJCC Cancer Staging Manual, 6th edn, New York: Springer, 2002.
  2. Davidson RS, Nwogu CE, Brentjens MJ, Anderson TM, The surgical management of pulmonary metastasis: current concepts, Surg Oncol, 2001;10:35–42.
  3. Labow DM, Buell JE, Yoshida A, et al., Isolated pulmonary recurrence after resection of colorectal hepatic metastases – is resection indicated? Cancer J, 2002;8:342–7.
  4. Sibley GS, Jamieson TA, Marks LB, et al., Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience, Int J Radiat Oncol Biol Phys, 1998;40:149–54.
  5. Sirzén F, Kjellén E, Sörenson S, et al., A systematic overview of radiation therapy effects in non-small cell lung cancer, Acta Oncol, 2003;42:493–515.
  6. McTaggart RA, Dupuy DE, Thermal ablation of lung tumors, Tech Vasc Interv Radiol, 2007;10:102–13.
  7. Vogl TJ, Naguib NN, Eichler K, et al., Volumetric evaluation of liver metastases after thermal ablation: long-term results following MR-guided laser-induced thermotherapy, Radiology, 2008;249:865–71.
  8. Goldberg SN, Grassi CJ, Cardella JF, et al., Image-guided tumor ablation: standardization of terminology and reporting criteria, J Vasc Interv Radiol, 2009;20:377–90.
  9. De Baère T, Lung tumor radiofrequency ablation: where do we stand? Cardiovasc Intervent Radiol, 2011;34:241–51.
  10. Lencioni R, Crocetti L, Cioni R, et al., Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study), Lancet Oncol, 2008;9:621–8.
  11. Hiraki T, Gobara H, Iishi T, Sano Y, Iguchi T, Fujiwara H, Tajiri N, Sakurai J, Date H, Mimura H, Kanazawa S, Percutaneous radiofrequency ablation for clinical stage I nonsmall cell lung cancer: results in 20 nonsurgical candidates, J Thorac Cardiovasc Surg, 2007;134:1306–12.
  12. Steinke K, Radiofrequency ablation (RFA). In: Vogl TJ, Helmberger TK, Mack MG, Reiser MF (eds), Percutaneous Tumor Ablation in Medical Radiology, 1st edn, Berlin, Heidelberg: Springer, 2008;179–96.
  13. Goldberg SN, Radiofrequency tumor ablation: principles and techniques, Eur J Ultrasound, 2001;13:129–47.
  14. Helmberger T, Radiofrequency. In: Vogl TJ, Helmberger TK, Mack MG, Reiser MF (eds), Percutaneous Tumor Ablation in Medical Radiology, 1st edn, Berlin, Heidelberg: Springer, 2008;7–20.
  15. Sharma A, Moore WH, Lanuti M, Shepard JA, How do I do it: radiofrequency ablation and cryoablation of lung tumors, J Thorac Imaging, 2011;26:162–74.
  16. Hiraki T, Gobara H, Mimura H, et al., Does tumor type affect local control by radiofrequency ablation in the lungs? Eur J Radiol, 2010;74:136–41.
  17. Simon CJ, Dupuy DE, DiPetrillo TA, et al., Pulmonary radiofrequency ablation: long-term safety and efficacy in 153 patients, Radiology, 2007;243:268–75.
  18. Sonntag PD, Hinshaw JL, Lubner MG, et al., Thermal ablation of lung tumors, Surg Oncol Clin N Am, 2011;20:369–87. 19. Guihaire J, Verhoye JP, de Latour B, Leguerrier A. Parietal tumor recurrence of lung metastasis after radiofrequency ablation, Interact Cardiovasc Thorac Surg, 2010;10:650–1.
  19. Simon CJ, Dupuy DE, Mayo-Smith WW, Microwave ablation: principles and applications, Radiographics, 2005; 25(Suppl. 1):S69–83.
  20. Boss A, Dupuy D, Pereira PL, Microwave. In: Vogl TJ, Helmberger TK, Mack MG, Reiser MF (eds), Percutaneous Tumor Ablation in Medical Radiology, 1st edn, Berlin, Heidelberg: Springer, 2008;21–8.
  21. Durick NA, Laeseke PF, Broderick LS, et al., Microwave ablation with triaxial antennas tuned for lung: results in an in vivo porcine model, Radiology, 2008;247:80–7.
  22. Brace CL, Hinshaw JL, Laeseke PF, et al., Pulmonary thermal ablation: comparison of radiofrequency and microwave devices by using gross pathologic and CT findings in a swine model, Radiology, 2009;251:705–11.
  23. Carrafiello G, Mangini M, De Bernardi I, et al., Microwave ablation therapy for treating primary and secondary lung tumours: technical note, Radiol Med, 2010;115:962–74.
  24. Wolf FJ, Grand DJ, Machan JT, et al., Microwave ablation of lung malignancies: effectiveness, CT findings, and safety in 50 patients, Radiology, 2008;247:871–9.
  25. Wright AS, Sampson LA, Warner TF, et al., Radiofrequency versus microwave ablation in a hepatic porcine model, Radiology, 2005;236:132–9.
  26. Vogl TJ, Naguib NN, Gruber-Rouh T, et al., Microwave ablation therapy: clinical utility in treatment of pulmonary metastases, Radiology, 2011;261:643–51.
  27. Feng W, Liu W, Li C, et al., Percutaneous microwave coagulation therapy for lung cancer, Zhonghua Zhong Liu Za Zhi, 2002;24:388–90.

Further Resources

Share this Article
Related Content In Lung Cancer
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72